Suven Pharmaceuticals rose 2.52% to Rs 765.75 after the company said its board fixed 28 September 2020 as the record date to ascertain shareholders eligible to receive bonus shares.
Last month, the board of Suven Pharma recommended issuing one bonus share for each share held (1:1).
The stock surged 339.83% from its 52-week low of Rs 174.10 hit on 24 March 2020.
The pharma company's consolidated net profit fell 0.4% to Rs 91.52 crore on a 20.7% increase in net sales to Rs 238.23 crore in Q1 June 2020 over Q1 June 2019.
Suven Pharmaceuticals is engaged in the business of contract development and manufacturing operations (CDMO).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app